Close Menu

CHICAGO (GenomeWeb) – Investigators in the National Cancer Institute's Molecular Analysis for Therapy Choice (MATCH) trial reported initial results for three treatment arms of the study at the American Society of Clinical Oncology's annual meeting here this week, finding that some patients with defined molecular tumor alterations responded to targeted drugs while others didn't.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.